Riskpilot← Back to searchSign inGet full accessPharmmina AB
ABActiveOrg 5593167637Tunavägen 51 DRetail sale of pharmaceutical products · NACE 4773Est. 20211-4 employees
Revenue 2024
SEK 9,6M
+38% vs 2023
EBITDA margin
3.3%
-59% vs 2023
Equity ratio
30.5%
Financial strength
Net profit 2024
SEK 153K
-71% vs 2023
| Revenue | SEK 9,6M | +38% |
| EBITDA | SEK 315K | -59% |
| Net profit | SEK 153K | -71% |
| Total assets | SEK 2,4M | +8% |
| Equity | SEK 732K | +26% |
| Employees | — | — |
Legal name
Pharmmina AB
Org number
5593167637
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
11 maj 2021
Share capital
SEK 25 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva öppenvårds- samt apoteksverksamhet, medicinsk och farmaceutisk konsultverksamhet, import och export av mediciner och därmed förenlig verksamhet.
Address
Tunavägen 51 D
Email
homam.adel@apoteksparta.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 2 828 | 6 956 | 9 573 |
| Staff expenses | — | — | −394 | −1 141 |
| EBITDA | — | −83 | 762 | 315 |
| Depreciation & amort. | −0 | −39 | −39 | −39 |
| EBIT | 0 | −122 | 723 | 276 |
| Net financials | — | −93 | −107 | −82 |
| Profit before tax | 0 | −216 | 615 | 194 |
| Tax | −0 | −0 | −80 | −41 |
| Net profit | 0 | −216 | 535 | 153 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 25 | 1 592 | 2 228 | 2 397 |
| Equity | 25 | 18 | 580 | 732 |
| Long-term debt | 0 | 1 484 | 597 | 366 |
| Short-term debt | 0 | 89 | 1 052 | 1 299 |
| Total debt | — | 1 573 | 1 649 | 1 665 |
EBITDA margin
3.3%
This company
15.8%
Market median
-79% vs market
20212024
Equity ratio
30.5%
This company
38.2%
Market median
+20% vs market
20212024
Return on equity
20.8%
This company
18.4%
Market median
+13% vs market
20212024
Net profit margin
1.6%
This company
8.1%
Market median
-80% vs market
20212024
Asset turnover
3.99×
This company
1.12×
Market median
+256% vs market
20212024
Debt / equity
2.27×
This company
0.62×
Market median
-266% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-05-01 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MA | Audit | 2026 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Deputy Board Member | 2025 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Board of Directors | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Pharmmina AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mats Anders Gyllenberg | Audit | 0 companies |
| Pia Carina Eriksson | Board of Directors | 0 companies |
| Lina Anna Elisabeth Nordström | Deputy Board Member | 0 companies |
| Riim Saadi Abdulridha Darwish Adel | Deputy Board Member | 0 companies |
| Nebil Charchafche | Deputy Board Member | 0 companies |
| Petra Maria Nilsson Andersson | Deputy Board Member | 0 companies |
| Henrik Daniel Karlsson | Deputy Board Member | 0 companies |
| Homam Ahmed Adel | Board of Directors | 0 companies |